The short version

The best-studied minimally invasive aesthetic treatment. Predictable when product, dose, placement, and injector are right; still a prescription biologic with a boxed warning.

What the cost figure means

$435 average physician fee. Average per treatment reported by ASPS; some practices price per unit. Excludes consultation and touch-ups; cosmetic use is self-pay. ASPS publishes this national average physician fee on its cost page as its latest statistic without stating the survey year, and its 2025 report no longer includes minimally invasive fees.

Advertised prices on file

$10–$16 per unit

Botox, Dysport, Xeomin, Daxxify, and Letybo per unit across five menus; one menu prices by area ($240–$940). ASPS's 2022 fee table put the average treatment at $528.

Read from 6 published U.S. clinic menus on September 1, 2026. A convenience sample, not a national survey: prices vary by city and provider, packages are usually cheaper per session, and menus change without notice.

Total course = per-session fee × planned sessions + consultation + product, cartridge, or serum + anesthesia or facility + prescriptions and aftercare + expected maintenance. Ask for the plan price in writing.

Healing and results timeline

Appointment
About 10–20 minutes
Downtime
None; small bumps for under an hour, bruising possible for up to a week
Healing
Injection marks fade within hours. Bruises, if any, resolve in about a week. Avoid rubbing the area or lying flat for a few hours as instructed.
Results appear
Change begins in 3–7 days; full effect around 2 weeks
Duration and maintenance
About 3–4 months, sometimes longer with repeat treatment

Benefits, limitations, and risks

Realistic benefits

  • Fast onset and little interruption
  • Dose can start conservatively and be adjusted
  • Decades of safety data at cosmetic doses

Limitations

  • Temporary and a recurring expense
  • Does nothing for static lines, pigment, pores, or volume loss
  • A frozen or asymmetric look if placement or dose is off

Common effects

  • Bruising
  • Headache
  • Temporary heaviness

Serious risks

  • Eyelid or brow droop lasting weeks
  • Facial asymmetry or difficulty with expressions
  • Rare spread of toxin effect causing swallowing or breathing problems (boxed warning)

Candidacy and pause signs

Usually considered for: Adults with movement-related lines who want a temporary, adjustable result.

Pause before booking if

You are pregnant or breastfeeding, have a neuromuscular condition, an infection at the site, are being offered an unnamed or imported product, or the injector will not show you the vial.

Operator, setting, and regulation

Who performs it in the U.S.: Physicians, and in most states nurse practitioners, physician assistants, or registered nurses under physician oversight. Rules on delegation and supervision vary by state; the product requires a prescription.

Regulatory status: Prescription biologics approved by FDA for specific facial lines; all carry a boxed warning about distant spread of toxin effect. FDA has issued warnings about counterfeit and unapproved botulinum toxin products sold to clinics.

Rules differ by state and by country. A product approved in one market may be unapproved in another, and the same device can be used within or outside its cleared indication.

Questions to ask before you pay a deposit

  1. Which product and how many units in each area?
  2. Who is the supervising physician, and how do you source the product?
  3. How will you handle a droop or asymmetry if it happens?

Open the complete safety checklist →

Use and market context

Popularity measures use, not effectiveness or safety. Each figure carries its source and its main methodological limit.

7.8MBotulinum toxin procedures worldwide, 2024ISAPS global survey 2024. Estimated from a survey of plastic surgeons only; dermatology and spa volumes are not included.
≈50%Share of minimally invasive treatments by ASPS members, 2025ASPS 2025 statistics report. A share of treatments, not a count; ASPS stopped publishing minimally invasive counts in 2025.

Sources on file

These links support the claims above. Reviewed September 1, 2026. Where a figure comes from a survey, the caveat is in the file, not in a footnote.

  1. American Academy of Dermatology — botulinum toxin overview (opens in a new tab)
  2. American Academy of Dermatology — botulinum toxin FAQs (opens in a new tab)
  3. U.S. FDA — Botox / Botox Cosmetic medication guide (opens in a new tab)
  4. U.S. FDA — warning letters over illegal marketing of Botox and related products (opens in a new tab)
  5. Aesthetic Plast Surg 2023 — botulinum toxin A for glabellar lines: network meta-analysis (PubMed) (opens in a new tab)
  6. Aesthetic Plast Surg 2025 — meta-analysis of adverse reactions of botulinum toxin A in facial rejuvenation (PubMed) (opens in a new tab)
  7. American Society of Plastic Surgeons — botulinum toxin cost (opens in a new tab)
  8. ISAPS — 2024 global survey on aesthetic/cosmetic procedures (opens in a new tab)June 19, 2025
  9. American Society of Plastic Surgeons — 2025 procedural statistics report (PDF) (opens in a new tab)2025 statistics
  10. American Society for Dermatologic Surgery — botulinum toxin (opens in a new tab)

Spot an error or a status change? Read how corrections and updates work →